Kadmon Holdings Inc (NASDAQ:KDMN) has been assigned a consensus recommendation of “Hold” from the eight research firms that are covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, two have given a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $9.80.

A number of research analysts recently weighed in on the company. Zacks Investment Research downgraded Kadmon Holdings from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. Piper Jaffray Companies set a $7.00 target price on Kadmon Holdings and gave the company a “buy” rating in a report on Wednesday, August 2nd. WBB Securities lowered Kadmon Holdings from a “hold” rating to a “sell” rating and set a $3.00 target price on the stock. in a report on Monday, October 9th. Finally, ValuEngine lowered Kadmon Holdings from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 1st.

Kadmon Holdings (NASDAQ:KDMN) traded up 1.15% during trading on Wednesday, reaching $3.51. The company’s stock had a trading volume of 168,258 shares. The firm’s market capitalization is $181.98 million. The stock’s 50-day moving average is $3.43 and its 200 day moving average is $3.43. Kadmon Holdings has a 52-week low of $2.05 and a 52-week high of $7.10.

Kadmon Holdings (NASDAQ:KDMN) last issued its quarterly earnings data on Thursday, August 3rd. The company reported ($0.44) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.49) by $0.05. The company had revenue of $3.00 million during the quarter, compared to the consensus estimate of $3.46 million. During the same period in the previous year, the business posted ($4.40) earnings per share. The firm’s revenue was down 53.1% on a year-over-year basis. On average, analysts predict that Kadmon Holdings will post ($1.55) EPS for the current fiscal year.

WARNING: This article was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/10/25/kadmon-holdings-inc-kdmn-given-average-recommendation-of-hold-by-brokerages.html.

In other Kadmon Holdings news, major shareholder Goldentree Asset Management Lp sold 302,950 shares of the firm’s stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $2.73, for a total value of $827,053.50. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders acquired a total of 14,707 shares of company stock worth $34,294 in the last ninety days.

Several large investors have recently made changes to their positions in the company. Wells Fargo & Company MN grew its holdings in shares of Kadmon Holdings by 17.0% during the 2nd quarter. Wells Fargo & Company MN now owns 60,033 shares of the company’s stock worth $234,000 after purchasing an additional 8,742 shares in the last quarter. Goldman Sachs Group Inc. acquired a new stake in shares of Kadmon Holdings during the 2nd quarter worth approximately $114,000. KCG Holdings Inc. acquired a new stake in shares of Kadmon Holdings during the 1st quarter worth approximately $124,000. Bank of New York Mellon Corp grew its holdings in shares of Kadmon Holdings by 302.3% during the 1st quarter. Bank of New York Mellon Corp now owns 46,304 shares of the company’s stock worth $167,000 after purchasing an additional 34,794 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in shares of Kadmon Holdings during the 1st quarter worth approximately $158,000.

About Kadmon Holdings

Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.

Analyst Recommendations for Kadmon Holdings (NASDAQ:KDMN)

Receive News & Ratings for Kadmon Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.